Overview

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This bioequivalence (BE) study is to satisfy FDA regulatory requirements for extended releases drug product transfer from Zwickau, Germany to Vega Baja, Puerto-Rico.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fesoterodine